Natco Pharma Limited announced its audited consolidated financial results for the quarter and year ended March 31, 2025.
Consolidated revenue from operations stood at ₹44,295 million for the year ended March 31, 2025, compared to ₹39,988 million for the year ended March 31, 2024.
Consolidated profit for the period after tax was ₹18,854 million for the year ended March 31, 2025, versus ₹13,883 million for the year ended March 31, 2024.
Basic and diluted earnings per share (EPS) stood at ₹105.26 for the year ended March 31, 2025, compared to ₹77.34 for the year ended March 31, 2024.
Standalone revenue from operations was ₹40,945 million for the year ended March 31, 2025, as against ₹35,689 million for the year ended March 31, 2024.
Standalone net profit for the year was ₹18,504 million compared to ₹13,066 million last year.
The results were reviewed by the Audit Committee and approved by the Board of Directors on 28 May 2025.